Physiomics wins cancer therapy deal

14th Aug 2014 15:41

Biology company Physiomics won a contract with an unidentified drug company on Thursday, boosting its shares by 18.75%.Under the deal, Physiomics will model immune therapy agents for cancer research by the end of the year on a fee-for-service basis.Physiomics' chief executive Mark Shadwick said: "We are extremely pleased to engage with this customer and also to gain our first project targeting immunomodulatory agents."In addition to the revenue generated from this project, Physiomics will benefit greatly from the experience gained building such models in this exciting area of cancer research."Shares rose 0.03p to 0.19p at 15.12 in London.JF